Hodgkin's lymphoma Posts on Medivizor
Navigation Menu

Hodgkin’s lymphoma Posts on Medivizor

How effective is long-term brentuximab vedotin treatment for patients with recurrent or non-responding Hodgkin’s lymphoma?

Posted by on Jan 12, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated long-term treatment with brentuximab vedotin (Adcetris) for patients with Hodgkin's lymphoma (HL) that has come back or stopped responding to treatment. This study concluded that this treatment had a long-term benefit for some patients. Some background Most patients with HL respond well to initial treatment....

Read More

Are prognostic scores still useful for predicting outcomes for patients with advanced Hodgkin’s lymphoma?

Posted by on Jan 8, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined if international prognostic scores (IPS) could help predict treatment outcomes for patients with advanced Hodgkin's lymphoma (HL). The authors found that the IPS system is losing its predictability as treatment strategies improve for these patients. Some background Patients with HL need to be treated...

Read More

Evaluating gemcitabine plus bendamustine for patients with non-responsive Hodgkin lymphoma

Posted by on Dec 28, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of gemcitabine (Gemzar) plus bendamustine (Treanda) in patients with Hodgkin lymphoma (HL) that has come back or stopped responding to treatment. This study found that this combination was well-tolerated and effective for these patients. Some background Immunotherapy remains a...

Read More

Evaluating combined modality treatment for young adults with Hodgkin lymphoma

Posted by on Dec 7, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study determined the safety and effectiveness of combined modality treatment for young adults with classical Hodgkin lymphoma (cHL). This study concluded that this treatment approach was well-tolerated and effective for these patients. Some background Chemotherapy regimens for pediatric patients with cHL are different from...

Read More

Evaluating the risk of lung side effects in older patients with Hodgkin lymphoma

Posted by on Nov 29, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated whether older patients with Hodgkin lymphoma (HL) were at high risk for developing lung side effects when treated with bleomycin (Blenoxane). The authors found that the odds of developing lung side effects increased significantly with age in these patients. Some background For patients with HL, age is one of...

Read More

Evaluating long-term outcomes for patients with nodular lymphocyte-predominant Hodgkin lymphoma

Posted by on Nov 29, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the long-term outcomes of first-line treatment in patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). The authors concluded that survival among these patients was similar to that of the general population. Some background NLPHL is a rare type of Hodgkin lymphoma. When diagnosed, most...

Read More

Evaluating immune-related side effects associated with pembrolizumab.

Posted by on Nov 29, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study wanted to find out what put patients at risk of having immune-related side effects when they were treated with pembrolizumab (Keytruda). The study found that patients with a higher body mass index (BMI; a measurement of weight in relation to height) and more cycles of treatment were more likely to determine immune-related side...

Read More

Early 18F-FDG PET/CT response can predict survival in patients with Hodgkin lymphoma treated with nivolumab

Posted by on Nov 17, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate if 18F-FDG PET/CT (ePET1) imaging can predict overall survival in patients with relapsed or unresponsive (refractory) Hodgkin lymphoma who have been treated with nivolumab.   This study concluded that ePET1 assessment can predict overall survival in these patients.  Some...

Read More